Navigation Links
Ambit Announces Participation At 12th Annual BIO Investor Forum

SAN DIEGO, Oct. 2, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the 12th Annual BIO Investor Forum to be held at the Palace Hotel in San Francisco, October 8-9, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, Quizartinib, at 2:30 p.m. PT/ 5:30 p.m. ET on Wednesday, October 9.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at  An audio replay will be available for 30 days following the initial presentation webcast. 

The 12th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. The BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

 Ambit Contacts: Marcy Graham

Ian Stone/David SchullExecutive Director, Investor Relations & Corp Comm

Media ContactsAmbit Biosciences, Inc.

Russo Partners858-334-2125


SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
2. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
3. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
4. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at
5. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
6. Ambit Biosciences to Present at Two Upcoming Investor Conferences
7. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
8. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
9. Sigma-Aldrich Announces Q3 2013 Earnings Conference Call
10. MUSA Announces Partnership with IPERION
11. Global Stem Cells Group, Inc. Announces Worldwide Alliance with EmCyte Corp. to Promote In-office Regenerative Medicine Solutions
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, ... VerMilyea will oversee all IVF lab procedures as well as continue his ... , “We traveled 7,305 miles to Auckland, New Zealand to bring home a High ...
(Date:11/30/2015)... ... ... announced the opening of a new core patient care hub with the opening of ... are part of GSCG’s expansion efforts in Latin America. , Both the Arica and ... from around the world. , The clinics will be headed by Victor Perez, M.D. and ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard Apparatus ... a biotechnology company developing bioengineered organ implants for ... notification from The NASDAQ Stock Market that it ... requirements. The letter noted that as a result ... stock having exceeded $1.00 per share for more ...
(Date:11/30/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... Genomics, Inc., a leading genome informatics company offering highly ... The San Diego -based company has ... and Co-founder, Ashley Van Zeeland , Ph.D., who is ... of the deal were not disclosed. ...
Breaking Biology Technology:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
Breaking Biology News(10 mins):